Macrovascular complications such as myocardial infarction, angina pectoris and cerebrovascular accidents are the major causes of mortality in diabetic patients [1, 2] . Although the maintenance of a good glycaemic control for a long period can decrease the risk of the development of diabetic microangiopathy [3] , the development of diabetic macroangiopathy cannot be prevented by glycaemic control [3, 4] . Therefore, it is very important to establish the pathogenesis of diabetic macroangiopathy.
As the rate-limiting enzyme of the polyol pathway, aldose reductase, can convert galactose to galactitol, which is only poorly metabolized by sorbitol dehydrogenase [13] . Galactose-feeding provides an enhanced flux through the first step of the polyol pathway and does not cause either hyperglycaemia, hypo-insulinaemia, hyperinsulinaemia or hyperlipidemia. Therefore, the galactosaemic animal is a suitable model for studying the effects of polyol pathway hyperactivity itself. The galactose model should also help to avoid problems resulting from the limited life-span of experimental animals and increased mortality associated with long-standing diabetes. Previous studies have shown functional, biochemical or morphological abnormalities in galactosaemic animals similar to those in diabetic neuropathy, retinopathy or nephropathy [14±20] . In addition, functional or biochemical deficits in galactosaemic rat aorta or aortic smooth muscle cells cultured with increased galactose concentrations [8, 21] suggest that galactose feeding could also cause diabetes-like macroangiopathy. Morphological analyses of galactose-induced macroangiopathy have, however, never been reported.
Our study was conducted to investigate whether activation of the polyol pathway by long-term treatment with galactose produced morphological changes in coronary arteries and the effect of an aldose reductase inhibitor, epalrestat [E-3-carboxymethyl-5-(2E-methyl-3-phenylpropenylidene) rhodamine] [22, 23] , was also studied.
Materials and methods
Animals. Healthy male beagle dogs (CSK Research Park, Nagano, Japan) aged 5 months were housed in separate cages and divided at random into four groups as follows: (1) ) (Oriental Yest Co., Tokyo, Japan) containing 30 % non-nutrient fibre or 30 % galactose, respectively. Epalrestat (Ono Pharmaceutical Co., Osaka, Japan) was given by gavage every day 1 h before feeding. The principles of laboratory animal care (NIH publication no. 85±23, revised 1995) were followed as well as the Animal Experimentation Guide of Nagoya University School of Medicine.
Morphological analysis. After 44 months of treatment, dogs were killed and the hearts and aortas were removed. Aortas were immediately frozen in liquid nitrogen and stored at ±80°C for assay of the galactitol content as described below. Hearts were preserved in 10 % formaldehyde, followed by dehydration through a graded series of ethanol. The samples were embedded in paraffin and the cross-sections (5 mm) at the level of bifurcation of left coronary arteries were stained with Elastica van Gieson for microscopic analysis using a computerized image analysis system (C´imaging systems, Compix Inc., Mars, Pa., USA). Morphometric analysis was done on the intimal and medial layers of coronary arteries which had a diameter of 300±800 mm. Six measurements in each sample were carried out and the mean value was taken as the representative. The personnel who quantified the change were blinded to the treatment.
Assay of galactitol contents in aortas and erythrocytes. Blood obtained at 42 months was centrifuged at 1000´g for 10 min at 4°C and the separated erythrocytes were washed twice with cold physiological saline and frozen at ±80°C until assay. Galactitol contents in aortas and erythrocytes were measured by a trimethylsilylether-based gas-liquid chromatographic method. The frozen aortas and erythrocytes were homogenized in 0.2 N ZnSO 4 containing 0.05 mmol a-methyl-d-mannoside as an internal standard. The solution mixture was heated at 50°C for 10 min and deproteinization was completed by the addition of 0.2 N Ba(OH) 2 . After centrifugation at 1000´g for 10 min at 4°C, the supernatant was evaporated and dried to a residue, which was silylcated with 0.1 ml of N-trimethylsilylimidazol (GL-Sciences, Tokyo, Japan) at 37°C for 1 h. The trimetylsilyc ethers formed were then assayed with gas chromatograph (GC-17 A, Shimazu Co., Kyoto, Japan).
Biochemical assay. An aliquot of the serum obtained above was subjected to biochemical analysis. Glucose was determined by an enzymatic analysis (the glucose C test, Wako Pure Chemicals, Osaka, Japan). Total cholesterol concentrations were also measured by enzymatic methods (Determiner TC-S; Kyowa Medex, Tokyo, Japan). Erythrocyte HbA 1 c values were measured by immunoassay (DCA-2000, Bayer-Sankyo Co., Tokyo, Japan).
Statistical analysis.
Results are presented as means ± SEM. Differences among experimental groups were detected by analysis of variance and the differences between groups was assessed by Scheffe's S test. Significance was defined as a p value less than 0.05.
Results
Body weight and biochemical data. There were no significant differences in body weight or serum concentrations of glucose and total cholesterol between control and untreated galactose-fed dogs (Table 1) . Erythrocyte HbA 1 c values in untreated galactose-fed dogs were significantly higher than those in control dogs ( Table 1) . Treatment of galactose-fed dogs with either high or low dose epalrestat did not alter these variables.
Morphology of coronary arteries. Representative light photomicrographs of coronary arteries of control and galactose-fed dogs treated with or without high-dose epalrestat are shown in Fig. 1 . Untreated galactose-fed dogs showed remarkable intimal thickening compared with control dogs (Fig. 1 ). This thickening was clearly diminished by treatment with highdose epalrestat (Fig. 1) . For the statistical analysis, the area of intimal layer was measured. Although there were no significant differences in the areas of intimal layer between each experimental condition, the areas of intimal layer in untreated galactose-fed dogs (0.19 ± 0.02 mm 2 ) were larger than those in con-trol dogs (0.15 ± 0.01) and treatment of galactose-fed dogs with low and high dose epalrestat decreased the areas of the intimal layer (low-dose: 0.16 ± 0.02, high-dose: 0.14 ± 0.03) (Fig. 2) . The larger arteries have larger areas of intimal layer and there was a great variation in the diameters of the arteries used for measurement of the areas of intimal layer. This could result in no significant differences. Therefore, the areas of medial layer were also measured to compensate for the differences in the diameters of the arteries, and the intimal thickness was expressed as the ratio of the areas of intimal layer to those of medial layer (IA:MA) as reported previously [24] . The IA:MA in untreated galactose-fed dogs (0.76 ± 0.03, p < 0.05) was significantly increased compared with that in control dogs (0.39 ± 0.03). Treatment of galactose-fed dogs with epalrestat significantly decreased the IA:MA in a dose-dependent fashion (low-dose: 0.56 ± 0.03, high-dose: 0.46 ± 0.02, p < 0.05) (Fig. 2) .
Galactitol content in aortas and erythrocytes. Galactitol was not detected in the aortas of control dogs. Untreated galactose-fed dogs had a remarkable accumulation of galactitol in their aortas (0.68 ± 0.12 nmol × mg protein ±1 ), which was significantly diminished by treatment with epalrestat in a dose-dependent fashion (low-dose: 0.47 ± 0.1, high-dose: 0.22 ± 0.03, p < 0.05) (Fig. 3 ). The effects of galctose feeding and epalrestat on galactitol content in erythrocytes were similar to those in aortas (Fig. 3 ).
Discussion
Our study showed that galactose feeding of beagle dogs for a long period caused intimal thickening in coronary arteries and galactitol accumulation in aortas and that these abnormalities were reduced by treatment with an aldose reductase inhibitor, epalrestat.
There are a few animal models of diabetes, such as mice [25] , rabbits [26] and hamsters [27] which morphologically show atherosclerotic lesions. In addition, diabetic animals have hyperlipidaemia, which is one of the most important atherogenic factors. Therefore, it is impossible to investigate the role of hyperglycaemia itself in the development of atherosclerosis in diabetic animals. Previous studies have shown that the galactose-fed animal would be a useful model for investigating the pathogenesis of diabetic microangiopathy [14±20]. Pericyte ghost formation, microaneurysms and acellular capillaries in the retinas, which are characteristic features of diabetic retinopathy in humans, have been found in galactose-fed dogs [14] . Diabetes-like preproliferative abnormalities such as intraretinal microvascular abnormalities, occluded arterioles, preretinal and intravitreal haemorrhage and neovascularization in optic discs have also been observed in galactosaemic dogs [15] . In addition, functional or morphological deficits similar to diabetic nephropathy or neuropathy have been detected in galactosaemic animals [16±20]. There are, however, few reports on macrovascular abnormalities in galactose-fed animal models, only biochemical or functional abnormalities of aortas consistent with those in diabetic animals have been reported [8, 21] .
Galactose can be reduced to galactitol by aldose reductase, a late-limiting enzyme of the polyol pathway which converts glucose to sorbitol, but galactitol is not a substrate of sorbitol dehydrogenase which catalyses the conversion of sorbitol to fructose [13] . Therefore, galactosaemic animals have been used mainly to investigate the pathogenesis of diabetic microangiopathy from the view point of polyol pathway hyperactivity and the efficacy of aldose reductase inhibitors for preventing the development of diabetic microangiopathy. As for macrovascular abnormalities, it was reported that activation of the diacylglycerol (DAG)-PKC pathway in galactosaemic aortas was not reduced by an aldose reductase inhibitor [8] . On the other hand, galactose-induced deficits in relaxation of aortas were prevented by aldose reductase inhibition [21] . Moreover, polyol accumulation and osmotic stress lead to compromised integrity of cell membranes [36] , which facilitates non-receptor-mediated uptake of oxidized low-density lipoproteins which are implicated in intimal thickening [37, 38] . Our study also morphologically confirmed that the intimal thickening of coronary arteries of galactosaemic dogs can be prevented by an aldose reductase inhibitor. Although metabolic alterations due to hypergalactosaemia, apart from an accumulation of intracellular galactitol remain unclear, these observations suggest that aldose reductase inhibitor-sensitive metabolic alterations are responsible for the development of diabetes-like macroangiopathy as well as microangiopathy.
Initially, sorbitol accumulation which increases intracellular osmolality was considered to have a key role in the polyol pathway hyperactivity hypothesis. In recent studies, polyol pathway-related metabolic alterations such as myo-inositol depletion [39] , increased oxidative stress [40] , glycation [41] or altered PKC activity [5] rather than sorbitol accumulation itself have gained attention as the pathogenic factors of diabetic complications. Previous observations described above [31±35] and the results of this study verify the importance of intracellular sorbitol accu- Increases in oxidative stress, glycation [42] and DAG-PKC activity [43] have been implicated in the pathogenesis of diabetic macroangiopathy. Polyol pathway hyperactivity have been considered to be related to these metabolic deficits through an alteration of the redox state [44] including a decrease in NAD-PH:NADP + and an increase in NADH:NAD + . The latter causes an increase in DAG-PKC activity but not in galactose-induced polyol pathway hyperactivity itself as described above. An increase in NADH: NAD + has, however, been found in galactosaemic animals and was prevented by an aldose reductase inhibitor [45] . In addition, activation of the DAG-PKC pathway has been shown in the galactosaemic aorta [8] . Although the precise mechanism mediating an increase in NADH:NAD + and PKC activity in hypergalactosaemia remains unclear and PKC activity was not measured in this study, these observations and that the aldose reductase inhibition prevented the intimal thickening suggest that galactose-induced intimal thickening is mediated through polyol pathwayinduced activation of the DAG-PKC pathway.
A decrease in NADPH:NADP + can be observed not only in hyperglycaemia but also in hypergalactosaemia, resulting in an increase in oxidative stress through a reduction in glutathione. Increased oxygen radicals initiate lipid peroxidation, which, in turn, stimulate protein glycation [46, 47] . Furthermore, galactitol can be metabolized to galactitol-2-phosphate and galactitol-3-phosphate [48] , which could be potent protein-glycating agents like fructose-3-phosphate [49] . Therefore, increased oxidative stress and the following acceleration of glycation in galactosaemia could be involved in the intimal thickening of coronary arteries. In fact, epalrestat prevented an increase in carboxymethyllysin, an advanced glycation end product, in aortas of galactosaemic dogs [50] . This could strongly support the close relation between increased polyol pathway activity and glycation in the development of diabetic macroangiopathy.
In summary, an intimal thickening of coronary arteries similar to that in diabetic macroangiopathy was observed in galactose-fed dogs concomitant with a remarkable accumulation of galactitol in their aortas and treatment with an aldose reductase inhibitor, epalrestat, significantly prevented these deficits. These observations suggest that polyol pathway hyperactivity is closely related to the development of diabetic macroangiopathy, which could be prevented by aldose reductase inhibition. 
